Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon Restructuring Efforts To Generate $30 Mil.-$40 Mil. In Annual Savings

This article was originally published in The Rose Sheet

Executive Summary

Revlon's second wave of recent corporate trimming is expected to generate annualized cost savings of $30 mil. to $40 mil., the company announced Jan. 11. The savings are a 38% increase over original projections of $25 mil. to $30 mil. in savings announced last fall ("The Rose Sheet" Oct. 5, 1998, p. 5). Revlon hopes to achieve $15 mil. to $20 mil. of the savings in 1999.

You may also be interested in...



Revlon

Cutbacks include the reduction of 200 U.S.-based employees and approximately 80 vacant posts in the company's New York and New Jersey locations, Revlon says Dec. 8. The layoffs will occur before Dec. 31 as part of Revlon's previously announced restructuring program. The majority of the staff reductions will take place at the company's New York City headquarters and New Jersey office, where staff will be cut by 11% and 6%, respectively. The cutbacks are in addition to the original 1,000 to 1,200 layoffs that occurred earlier in the year (1"The Rose Sheet" Jan. 18, p. 12)

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS006211

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel